Company news

GeoVax Labs, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

GeoVax Highlights New Study Demonstrating the Strength of Multi-Antigen COVID-19 Vaccine Candidates

April 16, 2025

GeoVax Provides Update on BARDA Project NextGen and Outlines 2025 Business Momentum

April 16, 2025

GeoVax to Present at the Emerging Growth Conference on April 16, 2025

April 15, 2025

GeoVax to Present Clinical Data at Upcoming April Industry Events

April 15, 2025

GeoVax Receives USPTO Notice of Allowance for Marburg Hemorrhagic Fever Vaccine Patent

April 9, 2025

GeoVax Reports 2024 Year-End Financial Results and Provides Business Update

March 27, 2025

GeoVax Labs Announces $4.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

March 24, 2025

GeoVax to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on March 27, 2025

March 17, 2025

GeoVax Establishing Strategic Presence in Europe With Initial Footprint in the UK

March 12, 2025

GeoVax to Present at the 37th Annual Roth Conference

March 11, 2025

GeoVax Highlights the Critical Role of MVA-Based Vaccines in U.S. Biodefense Strategy

March 3, 2025

GeoVax Response to WHO's Third Declaration of Mpox as a Public Health Emergency of International Concern

February 27, 2025

GeoVax Highlights the Role of MVA-Based Vaccines in Advancing Public Health Preparedness

February 24, 2025

Mpox Clade 1 in the U.S. Highlights the Need for Vaccine Supply Diversification

February 19, 2025

GeoVax Pledges Continued Support for Vaccine Innovation, Transparency, and Public Health

February 18, 2025

GeoVax to Present at the Emerging Growth Conference on February 19, 2025

February 17, 2025

GeoVax Announces Strategic Integration of AI in Support of President Trump's Stargate Initiative

February 2, 2025

Strengthening America's Biosecurity: GeoVax Advances Domestic Vaccine Capability

January 28, 2025

GeoVax Advanced MVA Manufacturing Process: Aimed to Enhance Vaccine Supply Worldwide

January 26, 2025

GeoVax Announces Major Gedeptin Milestone With Plans of Phase 2 Trial

January 14, 2025

GeoVax Achieves Significant Progress in Next-Generation COVID-19 Vaccine Development Throughout 2024

January 12, 2025

GeoVax to Review 2024 Progress at the Emerging Growth Conference on January 16, 2025

January 7, 2025

GeoVax to Review 2024 Progress at Biotech Showcase During J.P. Morgan Healthcare Week 2025

January 5, 2025

GeoVax Receives Notice of Allowance For Cancer Vaccine Patent

December 9, 2024

GeoVax Announces Positive Interim Data Review for Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia

November 18, 2024

GeoVax Labs Reports Third Quarter 2024 Financial Results and Provides Business Update Form 8 K

November 13, 2024

GeoVax Reports Third Quarter 2024 Financial Results and Provides Business Update

November 11, 2024

GeoVax to Report Third Quarter 2024 Financial Results and Provide Corporate Update on November 12, 2024

November 4, 2024

GeoVax to Raise Approximately $5.0 Million of Gross Proceeds in Offering Priced At-the-Market

August 28, 2024

GeoVax to Raise Approximately $8.5 Million of Gross Proceeds in Offering Priced Above-the-Market

August 20, 2024

GeoVax Appoints Teresa Lambe, Acclaimed Professor of Vaccinology and Immunology at the Oxford Vaccine Group, to Its Scientific Advisory Board

August 7, 2024

GeoVax Reports Second Quarter 2024 Financial Results and Provides Business Update

August 5, 2024

GeoVax Announces Phase 2 Plans for Gedeptin® Cancer Therapy Following Clinical Advisory Committee Review

July 30, 2024

GeoVax to Report Second Quarter 2024 Financial Results and Provide Corporate Update on August 6, 2024

July 29, 2024

GeoVax Labs to Raise Approximately $3.1 Million of Gross Proceeds in Offering Priced At the Market Form 8 K

July 12, 2024

GeoVax Provides First Half 2024 Business Update

July 8, 2024

GeoVax Partners with Allucent to Conduct Phase 2b Clinical Study of Next-Generation COVID-19 Vaccine Candidate with Funding from BARDA

June 26, 2024

GeoVax Labs Receives BARDA Project NextGen Award to Conduct Phase 2b Clinical Study Evaluating the Company’s Next Generation COVID 19 Vaccine Candidate, GEO CM04S1 Form 8 K

June 19, 2024

GeoVax Receives BARDA Project NextGen Award to Conduct Phase 2b Clinical Study Evaluating the Company's Next-Generation COVID-19 Vaccine Candidate, GEO-CM04S1

June 17, 2024

GeoVax Reports First Quarter 2024 Financial Results and Provides Business Update

May 13, 2024

GeoVax to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024

May 6, 2024

GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System

March 5, 2024

GeoVax Reports 2023 Year-End Financial Results and Provides Business Update

February 28, 2024

GeoVax Announces Multiple Patent Issuances and Allowances

February 12, 2024

GeoVax Reports Positive Interim Data From Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster

February 5, 2024

GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement

January 28, 2024

GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, Oncology

January 7, 2024

GeoVax Announces Gedeptin® Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer Patients

January 3, 2024

GeoVax Announces Gedeptin Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer Patients

January 3, 2024

GeoVax Announces Issuance of Malaria Vaccine Patent

January 2, 2024

← Newer news releases · Older news releases →

Calls

The 5 newest of 21 calls. Every call is listed under its year.

Decks

The 5 newest of 6 decks. Every deck is listed under its year.